Biotech Capital (ASX:BTC) shares have jumped to as high as $0.063 so far this month, from just $0.026 on the last day of July.
Shares in the company are currently trading at $0.055 and a market cap of around $4 million.
Interest in the stock has been climbing since Domenic Carosa, a high profile technology investor, took a position in March.
Then on the 1st August, BTC appointed Dr Richard Treagus as its chairman.
Dr Treagus is a physician and entrepreneur, with over 20 years’ experience in the international pharmaceutical and biotechnology industry.
Richard served as Chief Executive of Acrux (ASX: ACR) until 2012, and is currently a director of QRxPharma (ASX: QRX), and Executive Chairman of Neuren Pharmaceuticals (ASX Code:NEU).
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.
Add to My Watchlist
What is My Watchlist?
